It is true that more fail than succeed but of the companies that fail most had all their eggs in one basket, a billion shares on the register and deep in debt trying to scrape together trials. Orthocell is in a remarkable position, not only no debt but money in the bank, only 200 million shares and lots of the time consuming trial done or near done. Not to mention fda approved and near term income stream. Also a number of different products with many applications. If i had to compare it to any company i can think of i would say cochlear.
Think i have just talked myself into topping up again.
It is true that more fail than succeed but of the companies that...
-
- There are more pages in this discussion • 69 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OCC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
73.0¢ |
Change
0.095(15.0%) |
Mkt cap ! $152.9M | |||
| Open | High | Low | Value | Volume |
| 63.5¢ | 73.0¢ | 63.0¢ | $1.028M | 1.510M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 6300 | 72.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 73.0¢ | 39994 | 1 |
View Market Depth
| Last trade - 16.10pm 15/10/2024 (20 minute delay) ? |
| OCC (ASX) Chart |